Your session is about to expire
← Back to Search
Monoclonal Antibodies
Depemokimab for Asthma (SWIFT-1 Trial)
Phase 3
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) and week 52
Awards & highlights
Summary
This trial is testing a new medication called Depemokimab for people with severe asthma that isn't controlled by other treatments. These patients have high levels of a specific white blood cell called eosinophils. Depemokimab works by reducing these cells to help lower inflammation and improve asthma symptoms.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline (day 1) and week 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) and week 52
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Annualized rate of clinically significant exacerbations over 52 weeks
Secondary outcome measures
Annualized rate of exacerbations requiring hospitalization and/or Emergency department (ED) visit over 52 weeks
Change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score at Week 52 (scores on a scale)
Change from Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) total score at Week 52 (scores on a scale)
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Participants receiving GSK3511294 (Depemokimab)Experimental Treatment1 Intervention
Participants will be administered GSK3511294 (Depemokimab) along with SoC.
Group II: Participants receiving placeboPlacebo Group1 Intervention
Participants will be administered matching placebo along with SoC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GSK3511294 (Depemokimab)
2021
Completed Phase 3
~400
Find a Location
Who is running the clinical trial?
Iqvia Pty LtdIndustry Sponsor
109 Previous Clinical Trials
171,910 Total Patients Enrolled
4 Trials studying Asthma
2,764 Patients Enrolled for Asthma
GlaxoSmithKlineLead Sponsor
4,772 Previous Clinical Trials
8,106,508 Total Patients Enrolled
298 Trials studying Asthma
448,106 Patients Enrolled for Asthma
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,596 Previous Clinical Trials
6,143,885 Total Patients Enrolled
229 Trials studying Asthma
401,849 Patients Enrolled for Asthma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a pre-bronchodilator FEV1 less than 80% predicted.You have, or with high likelihood of having, asthma with an eosinophilic phenotype.You are allergic or intolerant to the ingredients in GSK3511294 or any other similar medications.You have taken certain medications called mepolizumab, reslizumab, or benralizumab in the last year, or you have tried other medications that target a specific protein called IL-5 or its receptor and they didn't work for you.You have certain conditions that can cause high levels of a specific type of white blood cell called eosinophils.You have a documented physician diagnosis of asthma for at least 2 years that meets the National Heart, Lung, and Blood Institute (NHLBI) guidelines or Global Initiative for Asthma (GINA) guidelines.
Research Study Groups:
This trial has the following groups:- Group 1: Participants receiving GSK3511294 (Depemokimab)
- Group 2: Participants receiving placebo
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger